NEW YORK (GenomeWeb) –GenePOC announced this week that Swiss pharmaceutical company Debiopharm has invested "tens of millions of dollars" into accelerating development of the Quebec City-based firm's molecular diagnostic platform and infectious disease assays.

The new funding will be used to support commercialization as well as to "continue our new assay development and have a constant flow of approximately two assays per year launched into the market," Herbert Torfs, GenePOC's vice president of business development and strategy, told GenomeWeb in an email.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.